Brief: Transcode Therapeutics Inc Nasdaq Determines Co Has Regained Compliance With Continued Listing Requirements
07/01/2025 13:15
Jan 7 (Reuters) - Transcode Therapeutics Inc RNAZ.O :
* TRANSCODE THERAPEUTICS INC: NASDAQ DETERMINES CO HAS
REGAINED
COMPLIANCE WITH CONTINUED LISTING REQUIREMENTS
Source text: ID:nPnb1GNJ3a
Further company coverage: RNAZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcode Therapeutics
See all newsBrief: TransCode Therapeutics Appoints John Tattory As Interim CFO
Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors